EuroPharma expands Green Bay headquarters, doubling facility size

Cheryl Hentz

Contributor

November 17, 2025

GREEN BAY – EuroPharma, Inc.® – the Green Bay-based parent company of the Terry Naturally® brand – is doubling its footprint with a major expansion at its headquarters on Challenger Drive in Green Bay, bringing the facility’s total size to about 60,000 square feet.

Founded in 2003, Founder and President Terry Lemerond said EuroPharma started with a modest 20,000-square-foot building that met its needs for several years.

But steady growth, Lemerond said, soon pushed the company to expand once – and now, once again.

“We thought we had enough space at the time, and we actually did,” he said. “But as we grew, we outgrew that space and had to add on. Somewhere between 2010 and 2012, we expanded to give us more space for warehousing and shipping, as well as offices for marketing, sales and so forth. So, we added another 10,000 square feet. Now, we’re doing another major expansion, going from 30,000 square feet to approximately 60,000 square feet.”

Having broken ground on the expansion a handful of months ago, Lemerond said the new addition is expected to be complete by April 2026.

Lemerond said it will expand the company’s warehouse capacity to provide space for more inventory and enhanced service to retailers and customers, as well as prepare for the many opportunities that lie ahead.

“It will give us the space we need to add the volume of the production that we bring in from our contract manufacturer,” he said. “It’s a little bit different phase of how we’re constructing our building because we’re just not adding on because we’re pretty much land-locked. So, we’ve had to make changes in the existing building to re-arrange what we had currently so we could break ground and come out the back side of the building.”

Lemerond said the project required relocating the company’s docking system and several other internal areas to make way for the expansion.

“The new building will be higher than normal, because we only had enough space where we could go up with our racking system,” he said. “But it will not be like a total two-story expansion.”

Growth reflective of company’s values

EuroPharma’s growth – and that of its Terry Naturally® brand – Lemerond said, underscores the company’s commitment to providing safe, science-backed dietary supplements to consumers across the nation and around the world.

“We make the highest quality you can possibly make,” he said. “We provide a lot of science to support our products. And the products work. We have more than a 70% repeat buy. When a customer buys our products, they will buy those products again, seven out of 10 times. That’s because they’re getting results from the products.”

Lemerond said EuroPharma focuses on evidence-based products, instead of marketing hype to drive sales.

“We put a lot of evidence out there, between the quality, the science, the study and the validity of the products,” he said. “So, people buy our products, they get results and are very, very happy with our products.”

Lemerond said the company’s dealers and retailers have been “exceptionally happy” with the products.

“They want to sell them because they know their customers are going to get results,” he said. “And they’ll come back to their stores to buy more products. It’s a win-win situation, because everybody gets results.”

Lemerond acknowledged that some Terry Naturally products come with a higher price tag – a reflection, he said, of its uncompromising quality.

“We make products with the highest-grade bulk materials, using the potencies that are made in the scientific studies,” he said. “We don’t short-change any of our products. We give the consumer the best products possible, and we want them to get results. Sometimes the products are very pricey, but that’s because of the ingredients.”

With more than 55 years of research and experience in the natural health industry, Lemerond said he has dedicated his career to developing innovative nutritional and botanical formulas.

Known for his innovation in the supplement field, Lemerond said he helped bring glucosamine sulfate and standardized Ginkgo biloba to the U.S. market.

Among EuroPharma’s better-known products, he said, is Curamin®, which has received numerous industry awards for pain relief.

“I’ve been voted by the entire industry to be the oldest person in the industry that has the greatest legacy to be left behind when I’m gone,” the 87-year-old Lemerond said. 

A personal health turnaround early in life, Lemerond said, set him on the path to researching and developing natural health products.

He said that in his 20s, he struggled with poor health, excess weight and an unhealthy diet – and described himself then as unhappy and difficult to be around.

“Then, three people who I call my human angels – one a Catholic priest; one a captain in the Marine Corps; and one a lady who owned a health food store in Green Bay – influenced me to change my life, to change my lifestyle, to change my diet and to exercise and get in shape,” he said.

Lemerond said his commitment to healthy living eventually led the owner of that local health food store to ask him to take over the business upon her retirement.

“I told her I couldn’t afford it – I was married and had two kids and was working two jobs,” he said. “She told me the price she wanted and gave me the store, telling me to pay her when I could. So, I took over the store and after 15 years in retail, I found a way to make better products, more effective products and a higher grade of quality products.”

Lemerond said he continued to own the health food store but hired others to manage it, and in 1982, started Enzymatic Therapy, a company much like EuroPharma.

“In 2000, an investor wanted to buy our building and our company,” he said. “So, I sold the company, thinking I was going to retire. But I didn’t like retirement – I was like a fish out of water. That’s when I started EuroPharma, Inc.”

Even though his current building was built in 2003, Lemerond said he was under a non-compete clause as part of the Enzymatic Therapy sale, meaning he couldn’t sell to consumers, locally or nationally, but he was able to sell on a business-to-business (B2B) basis. 

“I was pretty miserable during those seven years,” he said. “But I spent the time doing research and trying to find products that we were able to sell or find some bulk products that we could sell to other manufacturers that they could then sell. I had to wait for my non-compete contract to run out. When it did in 2007, I started selling products nationally as Terry Naturally.”

Diving in headfirst, Lemerond said he drew on years of research, experience and industry connections when building EuroPharma.

“In 18 years, we are doing better than companies that have been in the industry for 40 or 50 years, because we have such a jump on them,” he said. 

As EuroPharma’s sole researcher, Lemerond said he focuses on studying ingredients, their quality and new technologies that improve product effectiveness, absorption and overall quality.

“I’m constantly looking to rev up our science,” he said.

Lemerond said he also oversees the research EuroPharma does with City of Hope Hospital in Los Angeles.

“There’s a researcher there who heads up their natural, alternative product laboratory with about 40 lab technicians who are all medical doctors,” he said. “They research how to treat cancer. They use many of our products in their cancer research… We have had a few universities and other cancer institutions ask if they can use our products for research [as well]. So, we send them raw materials – capsules, or whatever they ask for.” 

Securing the future

In the company’s early days, Lemerond said the biggest challenge was financing rapid growth, which often outpaced available funds.

“Banks become your best friend,” he said. “You have to prove to them that you’re going to be successful. Once you do, they’re very happy to support your growth. Right now, we have no debt, we’re growing by leaps and bounds, we have a tremendous cash flow, we’re paying for our expansion with cash and we are substantially supported to get to the next phase.”

Lemerond said he credits much of his success to his employees, several of whom have worked with him for nearly 40 years, first at Enzymatic Therapy and now at EuroPharma.

In late 2016, Lemerond said he transitioned ownership of the company to his employees, making EuroPharma an Employee Stock Ownership Plan (ESOP).

“I’m an entrepreneur,” he said. “I have goals and dreams, and I know what I want to accomplish. But I can’t do everything.”

Lemerond said his success comes from surrounding himself with top talent to handle the key responsibilities.

“I’m not a finance person or a marketing person,” he said. “So, I find the highest-quality people [who are]. They do the [job] and activities that are necessary to make our company successful. I didn’t build this company – the staff that I have built the company.”

With no family members interested in taking over and a desire to avoid outsiders disrupting the company’s culture, Lemerond said transitioning EuroPharma to an ESOP was the logical choice.

“Why not let the people who helped build the company run the company?” he said.

Since becoming employee-owned, Lemerond said the nearly 100 EuroPharma employees have become more conscious of what they’re putting into the company daily. 

“They have a direct relationship with the company,” he said. “They have a vested interest in this company and have shares in the company.”

As for the future, Lemerond said his retirement is on the horizon, and the next step will be putting an exit strategy in place.

“I’ll be exiting in the next two or three years,” he said. “So, we’ve brought in a successor who will take over the company. She came on board Nov. 10. She’ll work under me or with me for the next two or three years, and we’ll make decisions about where we want to take the company.”

After he passes the torch, Lemerond said his successor will guide the company into the next phase.

“She’s an entrepreneur, plus she’s got all the business background, the business acumen, to build this business more than I did,” he said. “She’s going to be a tremendous asset to the company.”